Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Artery Disease, Diabetes, and Chronic Kidney Disease
Authors:
- James ShepherdJSJames Shepherd
- John J.P. KasteleinJKJohn J.P. Kastelein
- Vera A. BittnerVBVera A. Bittner
- Rafael CarmenaRCRafael Carmena
- Prakash C. DeedwaniaPDPrakash C. Deedwania
- Andrei BreaznaABAndrei Breazna
- Stephen DobsonSDStephen Dobson
- Daniel J. WilsonDWDaniel J. Wilson
- Andrea L. ZuckermanAZAndrea L. Zuckerman
- Nanette K. WengerNWNanette K. Wenger
- 1 August 2008
- journal article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 83 (8) , 870-879
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular DiseaseCirculation, 2006
- An Assessment of Statin Safety by NephrologistsThe American Journal of Cardiology, 2006
- Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 PatientsThe American Journal of Cardiology, 2006
- Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemiaAmerican Heart Journal, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?The American Journal of Cardiology, 2004
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Proteinuria Predicts Stroke and Other Atherosclerotic Vascular Disease Events in Nondiabetic and Non–Insulin-Dependent Diabetic SubjectsStroke, 1996